Skip to content

Cyclomics finalizes Oncode clinical proof-of-concept project

Our technology, CyclomicsSeq, has been used in a recent Clinical Proof-of-Concept(Cpoc) project funded by the Oncode Institute. In this project several patients with advanced head and neck cancer were monitored over several months to obtain information about responders and non-responders for the given treatment. The project was performed in collaboration with the Netherlands Cancer Institute and the University Medical Center Utrecht.

Jeroen de Ridder says: “Based on the results obtained in this CPoC project, we were able to confidently set the next steps towards validating our technology in clinical practice. As a next step, we aim to include more patient samples to confirm these results in a larger study group.”

For more information please see:

https://www.oncode.nl/news/cell-free-dna-biomarkers-can-help-to-identify-treatment-responders-and-non-responders-of-head-and-neck-cancer-patients